Brain metastases affect a significant percentage of patients with advanced extracranial
malignancies. Yet, the incidence of brain metastases remains poorly described, largely due …

Over the past 2 decades, there has been an extraordinary progress in the regimens
developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive …

The restrictive nature of the blood–brain barrier (BBB) creates a major challenge for brain
drug delivery with current nanomedicines lacking the ability to cross the BBB. Extracellular …

An estimated 20% of all patients with cancer will develop brain metastases, with the majority
of brain metastases occurring in those with lung, breast and colorectal cancers, melanoma …

PURPOSE Conventional wisdom has rendered patients with brain metastases ineligible for
clinical trials for fear that poor survival could mask the benefit of otherwise promising …

Background Patients with metastatic breast cancer (MBC) are living longer, but the
development of brain metastases often limits their survival. We conducted a systematic …

Background The features and survival of stage IV breast cancer patients with different
metastatic sites are poorly understood. This study aims to examine the clinicopathological …

Metastasis, involving the spread of systemic cancer to the brain, results in neurologic
disability and death. Current treatments are largely palliative in nature; improved therapeutic …

Background Patients with brain metastases (BM) from human epidermal growth factor
receptor 2 (HER2)-positive breast cancer represent a difficult-to-treat population …

Background It was unclear whether breast cancer subtypes are associated with the risk of
site-specific metastases. This study aimed to evaluate the relationship between molecular …